Ligand Binding Assays (LBA) Archives - AIT BioscienceAIT Bioscience


Category Archives for Ligand Binding Assays (LBA)

American Society of Mass Spectrometry in Indy

From June 4-8, the city of Indianapolis got the privilege of playing host to nearly 6500 scientists from around the world who gathered to discuss all aspects of using mass spectrometry in a wide variety of applications. Several of our scientists were able to attend talks, workshops, and short-courses on LC-MS for antibody drug conjugates, proteins, … read the full article » »

Other Categories: LC-MS/MS Methods, News

Tags: , , , , , ,

Comments Off on American Society of Mass Spectrometry in Indy


AIT Bioscience Attends Bio+Tech17 and AAPS NBC Conferences

AIT Biosciences recently attended the Bio+Tech17 Conference in Bethesda, Maryland from April 27-28, 2017 and the AAPS NBC Conference in San Diego, California from May 1-3, 2017. Below are summaries of both conferences:     Bio+Tech17 Conference   The conference is run by the MD Tech Council and seeks to bring together innovators from across the … read the full article » »

Other Categories: LC-MS/MS Methods, Proteins and LC-MS/MS, Special Topics, Uncategorized

Tags: , , , , , , , , ,

Comments Off on AIT Bioscience Attends Bio+Tech17 and AAPS NBC Conferences


AIT Bioscience Recognized with Awards at Recent WRIB

  WRIB (Workshop for Recent Issues in Bioanalysis) is an annual gathering of bioanalytical scientists from across the pharmaceutical industry spectrum. Attendees include big pharma and biopharmas, biotechs, CROs and multiple regulatory agencies working on both small and large molecule bioanalysis.   Ashley Brant and Dr. Neal Simmons represented AIT Bioscience (AITB) discussing LC-MS/MS assays, … read the full article » »

Other Categories: Proteins and LC-MS/MS, Special Topics

Tags: , , , , ,

Comments Off on AIT Bioscience Recognized with Awards at Recent WRIB


AIT Bioscience Offers New Screening Level Assay

AIT Bioscience Offers New Screening Level Assay     A fit-for-purpose approach to bioanalytical assay support balances intended use of data with regulatory requirements and budgets. FDA regulated studies (GLP Tox or Clinical) require the use of a fully validated bioanalytical assay. However, for non-regulated studies sponsors often ask themselves, and their bioanalytical CRO partners, … read the full article » »

Other Categories: Electronic Lab Notebooks (ELN), Screening Assay



Comments Off on AIT Bioscience Offers New Screening Level Assay


AIT Bioscience Strengthens its Team with Recent Hires

AIT Bioscience (AITB) continues to expand its team to add breadth and depth to our areas of expertise. We are excited to introduce three new employees, who have already been great assets to AITB.     John Pirro     John Pirro recently joined AITB’s business development team. John earned a B.S. in Cell Biology … read the full article » »



Comments Off on AIT Bioscience Strengthens its Team with Recent Hires


Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs

By: Frank Spriggs, Ligand Binding Assay Group Leader, and Ashley Brant, Program Manager   The potential of antibody drug conjugates (ADCs) to provide targeted therapies for cancers and other devastating diseases have made them popular candidates for drug development programs. However, as we discussed recently in Drug Discovery and Development, the failure of several ADCs … read the full article » »

Other Categories: Biomarkers, LC-MS/MS Methods, Partnerships



Comments Off on Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs


Therapeutic Peptides – Toeing the Line of Small and Large Molecule Bioanalysis

By: Bo Kowalczyk, Vice President of Business Development The pharmaceutical industry is so abuzz with the potential for biologic therapeutics that we often forget about peptide therapy. Despite boasting desirable qualities – low toxicity, high specificity, and high potency – the adoption of peptides into treatments faces many hurdles (Table 1). Design strategies that improve … read the full article » »

Other Categories: LC-MS/MS Methods



Comments Off on Therapeutic Peptides – Toeing the Line of Small and Large Molecule Bioanalysis


What Level of Bioanalytical Method Validation is Right for My Early Stage Drug Development Study?

By: Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager During late phase drug discovery, everyone follows well established FDA bioanalytical method validation guidelines. However, opinions vary widely about what validation is necessary for early- to mid-phase studies. We are often asked by our clients: “How robust do I need this assay to … read the full article » »

Other Categories: LC-MS/MS Methods, Partnerships



Comments Off on What Level of Bioanalytical Method Validation is Right for My Early Stage Drug Development Study?


Critical Reagents Consideration for Ligand Binding Assays

Ligand binding assays (LBAs) are bioanalytical procedures commonly used to support biotherapeutic development. These assays are used for the characterization of pharmacokinetics, biomarkers, and/or immunogenicity.  LBAs, unlike classic LC-MS/MS, utilize the interactions of a biotherapeutic and proteins used as critical reagents to detect the analyte of interest.  Therefore, special considerations must be made in the … read the full article » »

Other Categories: Biomarkers, ELISA, Immunoassay



Comments Off on Critical Reagents Consideration for Ligand Binding Assays


Biosimilar Drug Development-Establishing PK and Immunogenicity Equivalence

Biosimilar Drug Development07:29:59 How We (and the FDA) Establish PK and Immunogenicity Bioequivalence One key question AIT Bioscience regularly receives is: “Is it better to use two separate PK or immunogenicity assays to analyze the reference product and the biosimilar, or should we use a one-assay approach?” Our advice has always been in the interest … read the full article » »

Other Categories: ELISA, Immunoassay, Uncategorized

Tags: ,

Comments Off on Biosimilar Drug Development-Establishing PK and Immunogenicity Equivalence